STOCK TITAN

[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Roivant Sciences (ROIV) director James C. Momtazee reported routine equity activity on 10/20/2025. He received 789 Common Shares as a fully vested award under the company’s Non‑Employee Director Compensation Plan, recorded at $0 per share.

The company also executed a net settlement to cover taxes, withholding 158 shares at a price of $17.74. Following these transactions, Momtazee directly holds 108,543 Common Shares.

Roivant Sciences (ROIV) l'amministratore James C. Momtazee ha riferito attività azionaria di routine il 20/10/2025. Ha ricevuto 789 azioni ordinarie come premio completamente vestito secondo il piano di compensazione per i direttori non dipendenti della società, registrato a $0 per azione.

La società ha inoltre eseguito un regolamento netto per coprire le tasse, trattenendo 158 azioni al prezzo di $17.74. A seguito di queste transazioni, Momtazee detiene direttamente 108.543 azioni ordinarie.

Roivant Sciences (ROIV) el director James C. Momtazee informó actividad accionaria de rutina el 20/10/2025. Recibió 789 acciones comunes como un premio totalmente vestificado bajo el plan de compensación para directores no empleados de la empresa, registrado a $0 por acción.

La empresa también ejecutó un acuerdo neto para cubrir impuestos, reteniendo 158 acciones a un precio de $17.74. Tras estas transacciones, Momtazee posee directamente 108,543 acciones comunes.

로이반트 사이언스(ROIV) 이사 James C. Momtazee가 2025년 10월 20일에 일상적인 주식 활동을 보고했습니다. 그는 회사의 비임직원 이사 보상 계획에 따라 완전히 vest된 상으로 789 일반 주식을 받았으며, 주당 $0으로 기록되었습니다.

회사는 또한 세금을 충당하기 위한 순 정산을 수행하여 158 주$17.74의 가격으로 보유했습니다. 이 거래 이후 Momtazee는 직접 108,543 일반 주식을 보유합니다.

Roivant Sciences (ROIV) le directeur James C. Momtazee a signalé une activité d'actions de routine le 20/10/2025. Il a reçu 789 actions ordinaires en tant que récompense entièrement acquise dans le cadre du plan de rémunération des administrateurs non salariés de l'entreprise, enregistré à $0 par action.

L'entreprise a également procédé à un règlement net pour couvrir les impôts, en retenue 158 actions à un prix de $17,74 par action. Suite à ces transactions, Momtazee détient directement 108 543 actions ordinaires.

Roivant Sciences (ROIV) Direktor James C. Momtazee meldete routiniertes Aktienaktivität am 20.10.2025. Er erhielt 789 Stammaktien als vollständig vestierte Belohnung gemäß dem Vergütungsplan des Unternehmens für Nicht-Mächtige Direktoren, aufgezeichnet zu $0 pro Aktie.

Das Unternehmen führte außerdem eine Nettosiedlung durch, um Steuern abzudecken, wobei 158 Aktien zum Preis von $17,74 einbehalten wurden. Nach diesen Transaktionen hält Momtazee direkt 108.543 Stammaktien.

رويفانت ساينسز (ROIV) مدير جيمس سي. مومتازي أبلغ عن نشاط أسهم روتيني في 20/10/2025. تلقى 789 سهماً عادياً كجائزة مكتملة الاستحقاق وفقاً لخطة تعويض المدراء غير الموظفين للشركة، مسجلة عند $0 للسهم.

كما نفذت الشركة تسوية صافية لتغطية الضرائب، مع خصم 158 سهماً بسعر $17.74 للسهم. عقب هذه المعاملات، يمتلك مومتازي مباشرة 108,543 سهماً عادياً.

Positive
  • None.
Negative
  • None.

Roivant Sciences (ROIV) l'amministratore James C. Momtazee ha riferito attività azionaria di routine il 20/10/2025. Ha ricevuto 789 azioni ordinarie come premio completamente vestito secondo il piano di compensazione per i direttori non dipendenti della società, registrato a $0 per azione.

La società ha inoltre eseguito un regolamento netto per coprire le tasse, trattenendo 158 azioni al prezzo di $17.74. A seguito di queste transazioni, Momtazee detiene direttamente 108.543 azioni ordinarie.

Roivant Sciences (ROIV) el director James C. Momtazee informó actividad accionaria de rutina el 20/10/2025. Recibió 789 acciones comunes como un premio totalmente vestificado bajo el plan de compensación para directores no empleados de la empresa, registrado a $0 por acción.

La empresa también ejecutó un acuerdo neto para cubrir impuestos, reteniendo 158 acciones a un precio de $17.74. Tras estas transacciones, Momtazee posee directamente 108,543 acciones comunes.

로이반트 사이언스(ROIV) 이사 James C. Momtazee가 2025년 10월 20일에 일상적인 주식 활동을 보고했습니다. 그는 회사의 비임직원 이사 보상 계획에 따라 완전히 vest된 상으로 789 일반 주식을 받았으며, 주당 $0으로 기록되었습니다.

회사는 또한 세금을 충당하기 위한 순 정산을 수행하여 158 주$17.74의 가격으로 보유했습니다. 이 거래 이후 Momtazee는 직접 108,543 일반 주식을 보유합니다.

Roivant Sciences (ROIV) le directeur James C. Momtazee a signalé une activité d'actions de routine le 20/10/2025. Il a reçu 789 actions ordinaires en tant que récompense entièrement acquise dans le cadre du plan de rémunération des administrateurs non salariés de l'entreprise, enregistré à $0 par action.

L'entreprise a également procédé à un règlement net pour couvrir les impôts, en retenue 158 actions à un prix de $17,74 par action. Suite à ces transactions, Momtazee détient directement 108 543 actions ordinaires.

Roivant Sciences (ROIV) Direktor James C. Momtazee meldete routiniertes Aktienaktivität am 20.10.2025. Er erhielt 789 Stammaktien als vollständig vestierte Belohnung gemäß dem Vergütungsplan des Unternehmens für Nicht-Mächtige Direktoren, aufgezeichnet zu $0 pro Aktie.

Das Unternehmen führte außerdem eine Nettosiedlung durch, um Steuern abzudecken, wobei 158 Aktien zum Preis von $17,74 einbehalten wurden. Nach diesen Transaktionen hält Momtazee direkt 108.543 Stammaktien.

رويفانت ساينسز (ROIV) مدير جيمس سي. مومتازي أبلغ عن نشاط أسهم روتيني في 20/10/2025. تلقى 789 سهماً عادياً كجائزة مكتملة الاستحقاق وفقاً لخطة تعويض المدراء غير الموظفين للشركة، مسجلة عند $0 للسهم.

كما نفذت الشركة تسوية صافية لتغطية الضرائب، مع خصم 158 سهماً بسعر $17.74 للسهم. عقب هذه المعاملات، يمتلك مومتازي مباشرة 108,543 سهماً عادياً.

罗万特科学公司 (ROIV) 董事 James C. Momtazee 报告了例行的股票活动,日期为 2025/10/20。他作为公司非雇员董事报酬计划下的完全归属的奖赏获得了 789 股普通股,每股记录价格为 $0

公司还执行了净和解以覆盖税费,扣留 158 股,价格为 $17.74。在这些交易之后,Momtazee 直接持有 108,543 股普通股

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MOMTAZEE JAMES C

(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDON X0 SW1H 0DB

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/20/2025 A 789(1) A $0(1) 108,701 D
Common Shares 10/20/2025 F 158(2) D $17.74 108,543 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.
2. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.
By: /s/ Jo Chen, as Attorney-in-Fact for James C Momtazee 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did ROIV report?

Director James C. Momtazee reported a grant of 789 Common Shares and a tax withholding of 158 shares via net settlement.

How many ROIV shares were awarded to the director?

He received 789 Common Shares, fully vested on the grant date under the Non‑Employee Director Compensation Plan.

What does the 158-share transaction represent for ROIV?

It reflects tax withholding via net settlement, with 158 shares withheld at $17.74.

What is the director’s ROIV share ownership after these transactions?

He directly owns 108,543 Common Shares.

What were the Form 4 transaction codes for ROIV?

Code A for the 789-share award and code F for the 158-share tax withholding.

Was the ROIV share award vested?

Yes. The filing states the award was fully vested as of the grant date.
Roivant Sciences

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Latest SEC Filings

ROIV Stock Data

12.37B
425.86M
26.13%
76.8%
5.72%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON